Accelerated clearance systems

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 315-324

  Sharma, S K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

ADEPT; antibody enzyme conjugates; clearance; inactivation

Indexed keywords

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY ENZYME CONJUGATES; AVIDIN; BIOTIN; CLEARANCE; PLASMA ENZYME ACTIVITY; TUMOUR;

ANTIBODIES; BLOOD; DISEASES; ENZYMES; TISSUE; TOXICITY;

DRUG THERAPY;

ANTIBODY; ANTIBODY CONJUGATE; AVIDIN; BIOTIN; ENZYME; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CLEARANCE; ENZYME BLOOD LEVEL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TISSUE DISTRIBUTION; TUMOR LOCALIZATION;

EID: 0030589713     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00441-3     Document Type: Review

References (60)

1. [1] Bagshawe, K.D. (1987) Antibody directed enzymes revive anticancer prodrugs concept. Br. J. Cancer 56, 531-532.
2. [2] Senter, P.D., Saulnier, M.G., Schreiber, G.J.M., Hirschberg, D.L., Brown, J.P., Hellstrom, I. and Hellstrom, K.E. (1988) Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85, 4842-4846.
3. [3] Buchegger, F., Pelegrin. A., Delaloye, B. et al. (1990) Iodine 131-labelled MAb F(ab′)2 fragments are more efficient and less toxic than intact CEA antibodies in radioimmunotherapy of large human colon carcinoma xenografted in nude mice. J. Nucl. Med. 31, 1035-1044.
4. [4] Pedley, R.B., Boden. J.A., Boden, R., Dale, R. and Begent, R.H.J. (1993) Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131-I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer 68, 69-73.
5. [5] Meyer, D.L., Jungheim, L.N., Law, K.L. et al. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res, 53, 3956-3963.
6. [6] Bosslet, K., Czech, J. and Hoffman, D. (1994) Tumour-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54, 2151-2159.
7. [7] Michael, N.P., Chester, K.A., Melton, R.G. et al. (1996) In vitro and in vivo characterization of a recombinant carboxypeptidase g(2) anti-CEA SCFV fusion protein. Immunotechnology 2(1), 47-57.
8. [8] King, D.J., Turner, A., Farnsworth, A.P.H. et al. (1994) Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54, 6176-6185.
9. [9] Antoniw, P., Farnsworth, A.P.H., Turner, A. et al. (1996) Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br. J. Cancer 74, 513-524.
10. [10] Govindan, S.V., Goldenberg, D.M., Grebenau, R.C., Hansen, H.J., Griffiths, G.L. (1996) Thiolations, TC-99M labellings, and animal in vivo biodistributions of divalent monoclonal-antibody fragments. Bioconjugate Chem. 7(3), 290-297.
11. [11] Hu, S., Shively, L., Raubitschek, Sherman, M., Williams et al. (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56, 3055-3061.
12. [12] Werten, R.C., Lankinen, M., Offord, R.E., Schubiger, P.A., Smith, A. and Rose, K. (1996) Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application. Cancer Res. 56, 809-815.
13. [13] Begent, R.H.J., Keep, P.A., Green, A.J. et al. (1982) Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet ii, 739.
14. [14] Barrat, G.M., Ryman, B.E., Begent, R.H.J., Keep, P.A., Searle, F., Boden, J.A. and Bagshawe, K.D. (1983) Improved radioimmunodetection of tumours using liposome-entrapped antibody. Biochirn. Biophys. Acta 762, 154-164.
15. [15] Bradwell, A.R., Vaughan, A., Fairweather, D.S. and Dykes, P.W. (1983) Improved radioimmunodetection of tumours using second antibody. (Letter to the Editor). Lancet i, 247.
16. [16] Chester, K.A., Begent, R.H.J., Pedley, R.B., Keep, P.A., Boden, J.A., Searle, Bagshawe, K.D. (1984) The use of second antibody to improve selective localisation of tumours: animal model studies. Br. J. Cancer 50, 556.
17. [17] Sharkey, R.M., Primus, F.J. and Goldenberg, D.M. (1984) Second antibody clearance of radiolabelled antibody in cancer radioimmunodetection. Proc. Natl. Acad. Sci. (USA) 81, 2843.
18. [18] Goldenberg, D.M., Sharkey, R. and Ford, E. (1987) Anti-antibody enhancement of iodine-131-anti-CEA radioimmunodetection in experimental and clinical studies. J. Nucl. Med. 28(10), 1604-1610.
19. [19] Begent, R.H.J., Chester, K.A., Bagshawe, K.D. et al. (1989) Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies. Clin. Exp. Immunol. 78, 307-313.
20. [20] Pedley, R.B., Dale, R., Boden, J.A., Begent, R.H.J., Keep, P.A. and Green, A.J. (1989) The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumour xenograft model. Int. J. Cancer 43, 713-718.
21. [21] Begent, R.H.J., Ledermann, J.A., Green, A.J., Bagshawe, K.D., Riggs, S.J. et al. (1989) Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br. J. Cancer 60, 406-412.
22. [22] Ullen, A., Sanderstrom, P., Ahlstrom, K.R., Sundstrom, B., Nilsson, B., Arlestig, L. and Stigbrand, T. (1995) Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumour: non-tumour ratio in experimental radioimmunolocalisation. Cancer Res. (Suppl) 55, 5868s-5873s.
23. [23] Klibanov, A.L., Martynov, A.V., Slinkin, M.A. et al. (1988) Blood clearance of radiolabelled antibody: enhancement by lactosamination and treatment with biotin-avidin or antimouse IgG antibodies. J. Nucl. Med. 29, 1951-1956.
24. [24] Kobayashi, H., Sakahara, H., Hosono, M., Yao, Z.S., Toyama, S., Endo, K. and Konishi, J. (1994) Improved clearance of radiolabelled biotinylated monoclonal antibody following the infusion of avidin as a 'chase' without decreased accumulation in the target tumour. J. Nucl. Med. 35, 1677-1684.
25. [25] Sinitsyn, V.V., Mamontova, A.G., Checkneva, Y.Y., Shnyra, A.A., and Domogatsky, S.P. (1989) Rapid blood clearance of biotinylated IgG after infusion of avidin. J. Nucl. Med. 30, 66-69.
26. [26] Paganelli, G., Stella, M., De Nardi, P., Magnani, P., Zito, F., Siccardi, G., Di Carlo, V. and Fazio, F. (1990) A new method for faster blood clearance in radioimmuno-guided surgery. J. Nucl. Med. Allied Sci. 35, 88-89.
27. [27] Paganelli, G., Belloni, C., Magnani, P. et al. (1992) Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur. J. Nucl. Med. 19, 322-329.
28. [28] Marshall, D., Pediey, R.B., Boden, J.A., Boden, R. and Begent, R.H.J. (1994) Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br. J. Cancer 69, 502-507.
29. [29] Sung, C., Van Osdol, W.W., Saga, T., Neumann, R.D., Dedrick, R.L. and Weinstein, J.N. (1994) Streptavidin distribution in metastatic tumours pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res. 54, 2166-2175.
30. [30] Kassie, A.I., Jones, P.L., Matalka, K.Z. and Adelstein, S.J. (1996) Antibody-dependent signal amplification in tumour xenografts after pretreatment with biotinylated monoclonal antibody and avidin or streptavidin. J. Nucl. Med. 37, 343-352.
31. [31] Otsuji, E., Yamaguchi, T., Matsumura, H. et al. (1996) Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin. Br. J. Cancer 74, 597-602.
32. [32] Paganelli, G., Magnani, P., Zito, F. et al. (1991) Three-step monoclonal antibody tumour targeting in carcinoembryonic antigen positive patients. Cancer Res. 51, 5960-5966.
33. [33] Saga, T., Weinstein, J.N., Jeong, J.M. et al. (1994) Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabelled streptavidin. Cancer Res. 54, 2160-2165.
34. [34] Yao, Z., Zhang, M., Kobayashi, H., Sakahara, H., Nakada, H., Yamashina, I. and Konishi, J. (1995) Improved targeting of radiolabelled streptavidin in tumours pretargeted with biotinylated monoclonal antibodies through an avidin chase. J. Nucl. Med. 36, 837-841.
35. [35] Rowlinsonbusza, G., Hnatowich, D.J., Rusckowski, M., Snook, D. and Epenetos, A.A. (1993) Xenograft localization using pretargeted streptavidin-conjugated monoclonal-antibody and IN(111)-labelled biotin. Antibody Immunoconjugates Radiopharm. 6(2) 97-109.
36. [36] Marshall, D., Pedley, R.B., Melton, R.G., Boden, J.A., Boden, R., and Begent, R.H.J. (1995) Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab′)2 fragments of an anti-tumour antibody. Br. J. Cancer 71, 18-24.
37. 125I-labelled monoclonal antibody L6. Antibody Immunoconjugates Radiopharm. 7(1), 29-42.
38. [38] Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
39. [39] Melton, R.G., Boyle, J.M.B., Rogers, G.T., Burke, P.J., Bagshawe, K.D. and Sherwood, R.F. (1992) Optimisation of small scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J. Immunol. Methods 158, 49-56.
40. [40] Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, R.W. and Rogers, G.T. (1990) Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br. J. Cancer 61, 659-662.
41. [41] Mattes, M.J. (1987) Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J. Natl. Cancer Inst. 79, 850-863.
42. [42] Ashwell, G. and Morell, A.G. (1974) The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. 41, 99-128.
43. [43] Thornberg, R.W., Day, J.F., Baynes, J.W. and Thorpe, S.R. (1980) Carbohydrate-mediated clearance of immune complexes from circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes. J. Biol. Chem. 255, 6820-6825.
44. [44] Sharma, S.K., Bagshawe, K.D., Springer, C.J., Burke, P.J., Rogers, G.T. and Boden, J.A. (1991) Antibody directed enzyme prodrug therapy ADEPT: A three phase system, Dis. Markers 9, 225-231.
45. [45] Eno-Amooquaye, E.A., Searle, F., Boden, J.A., Sharma, S.K. and Burke, P.J. (1996) Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol. Br. J. Cancer 73, 1323-1327.
46. [46] Rogers, G.T., Burke, P.J., Sharma, S.K., Koodie, R. and Boden, J.A. (1995) Plasma clearance of an antibody-enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Br. J. Cancer 72, 1357-1363.
47. [47] Bagshawe, K.D., Sharma, S.K., Springer, C.J., Antoniw, P., Boden, J.A., Rogers, G.T. et al. (1991) Antibody directed enzyme prodrug therapy (ADEPT): Clinical Report. Dis. Markers 9, 233-238.
48. [48] Bagshawe, K.D., Sharma, S.K., Springer, C.J. and Antoniw, P. (1995) Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumour Targeting 1, 17-29.
49. [49] Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, J.A., Rogers, G.T. et al. (1994) Galactosylated antibodies and antibody-enzyme conjugates in antibody directed enzyme prodrug therapy. Cancer 73(3), 1114-1120.
50. [50] Ong, G.L., Ettenson, D., Sharkey, R.M., Marks, A., Baumal, R., Goldenberg, D.M. and Mattes, M.J. (1991) Galactoseconjugated antibodies in cancer therapy: properties and principles of action. Cancer Res. 51, 1619-1626.
51. [51] Marshall, D. (1996) Investigations of clearance systems in antibody targeted therapy of cancer. Ph.D. Thesis, University of London.
52. [52] Kerr, D.E., Garrigues, U.S., Wallace, P.M., Hellstrom, K.E., Hellstrom, I. and Senter, P.D. (1993) Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of cytosine deaminase immunoconjugate. Biconjugate Chem. 4(5), 353-357.
53. [53] Wallace, P.M., MacMaster, J.F., Smith, V.F., Kerr, D.E., Senter, P.D. and Cosand, W.L. (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 54, 2719-2723.
54. [54] Pimm, M.V., Demignot, S. and Gribben, S.J. (1993) Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments. J. Cancer Res. Clin. Oncol. 119, 408-414.
55. [55] Ong, G.L., Marria, V. and Mattes M.J. (1994) The fate of antibodies and their radiolabels bound to tumour cells in vitro - the effect of cross-linking at the cell-surface and of anti-idiotype antibodies. Cancer Immunol. Immunother. 39, 325-331.
56. [56] Haisma, H.J., Van Muijen, M., Scheffer, G., Scheper, R.J., Pinedo, H.M. and Boven, E. (1995) A monoclonal antibody against human β-glucuronidase for application in antibody-directed enzyme prodrug therapy. Hybridoma 14(4), 377-382.
57. [57] Springer, C.J., Bagshawe, K.D., Sharma, S.K., Searle, F., Boden, J.A. et al. (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 27, 1361-1366.
58. [58] Blakey, D.C., Valcaccia, B.E., East, S. et al. (1993) Antitumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys. 22, 1-8.
59. [59] Sharma, S.K., Boden, J.A., Springer, C.J., Burke, P.J. and Bagshawe, K.D. (1994) Antibody directed enzyme prodrug therapy (ADEPT): a three-phase study in ovarian tumour xenografts. Cell Biophys. 24, 219-228.
60. [60] Blakey, D.C., Burke, P.J., Davies, D.H. et al. (1996) ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumour regressions in colorectal tumour xenografts. Cancer Res. 56, 3287-3292.